FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. FDA approves Ennumo (pegfilgrastim-pccg), a ...
BC, OCN, ONN-CG, an oncology nurse navigator and clinical advocate at Hackensack Meridian Ocean University Medical Center, ...
PADCEV (enfortumab vedotin-ejfv) can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly ...
The core of this optimization strategy is the geriatric assessment. At Mount Sinai, Jakubowski noted that patients aged 65 and older — and in some cases, those 60 and older — receive a comprehensive ...
Long-term data show watch-and-wait is viable for rectal cancer, with most regrowths salvageable despite adverse baseline MRI features. Long-term data presented at the ESMO GI 2026 Congress provide new ...
A real-world study presented at ESMO GI shows fruquintinib is effective in mCRC, with the best outcomes in the third-line setting. Findings from a retrospective, real-world analysis presented at the ...
Pamela Plasket, RN, discusses the evolving role of oncology nurses as lung cancer patients survive longer on advanced therapies like BiTEs. The landscape of thoracic oncology is undergoing a ...
Oncology nurse Kerry Mann details the protocols and patient-centered strategies for bringing advanced precision medicine to local community clinics. The landscape of cancer care is shifting as ...
Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates. As MetLife Stadium in East Rutherford, New ...
The FDA approved Azurity’s Aprepitant Injectable Emulsion, a polysorbate-80-free, ready-to-use IV option for preventing chemotherapy-induced nausea. The U.S. Food and Drug Administration (FDA) has ...
The FDA approved Tregzi, a precision-engineered cell therapy, to improve chronic GVHD-free survival in adults undergoing allogeneic transplant. The U.S. Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results